Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Refutes Claims of Third Wave Lawsuit

NEW YORK, Sept. 17 (GenomeWeb News) - In response to a suit filed by Third Wave Technologies for allegedly violating patents covering invasive cleavage structure chemistry, Stratagene responded today by saying that the claims lacked merit.

            "We are surprised that Third Wave would file this lawsuit before discussing with us the differences in the two companies' technologies," said Dr. Joseph Sorge, Stratagene's Chairman and CEO. "We believe that the filing of this action by Third Wave indicates that Third Wave views Stratagene's new technology as a serious competitive threat."

            The patent infringement suit filed in US District Court in Madison, Wisconsin, seeks a permanent injunction against Stratagene that would prevent the sale of the company's probe-based quantitative PCR and RT-PCR reagents. It claims that Stratagene violates some of the more than 30 patents that protect Third Wave's Invader products, which use invasive cleavage structure chemistry to analyze nucleic acids and infectious agents.

            In the past, a similar suit was brought by Third Wave against EraGen Biosciences Inc. of Madison, Wis. The patent violation suit was settled in the same US District Court and resulted in Eragen's removal from the market of the products in question.

            "The suit filed [against Stratagene] by Third Wave is part of our ongoing effort to aggressively protect the value of our patent portfolio on behalf of our shareholders," said John Puisis, president and CEO of Third Wave.

            Stratagene's CEO said his company's patents in the area of cleavage chemistry cover technologies that differ from Third Wave's patented technologies.

            "Stratagene does not include overlapping DNA molecules in its kits," said Sorge. "In contrast, Stratagene's Full Velocity technology benefits from the sensitivity advantages of PCR amplification, something not found in Third Wave's Invader methods."

            Stratagene's FullVelocity technology, which Third Wave objects to for allegedly infringing upon their patent rights, is covered by US patents 6,350,580; 6,528,254 and 6,548,250.

 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.